Azithromycin and early allograft function after lung transplantation: A randomized, controlled trial

被引:17
|
作者
Van Herck, Anke [1 ]
Frick, Anna E. [1 ,2 ,3 ]
Schaevers, Veronique [1 ]
Vranckx, Annelies [4 ]
Verbeken, Eric K. [5 ]
Vanaudenaerde, Bart M. [1 ]
Sacreas, Annelore [1 ]
Heigl, Tobias [1 ]
Neyrinck, Arne P. [2 ]
Van Raemdonck, Dirk [1 ,3 ]
Dupont, Lieven J. [1 ]
Yserbyt, Jonas [1 ]
Verleden, Stijn E. [1 ]
Verleden, Geert M. [1 ]
Vos, Robin [1 ]
机构
[1] Katholieke Univ Leuven, Lung Transplant Unit, Dept Chron Dis Metab & Ageing, Leuven, Belgium
[2] Katholieke Univ Leuven, Dept Cardiovasc Sci, Leuven, Belgium
[3] Univ Hosp Leuven, Dept Thorac Surg, Leuven, Belgium
[4] Univ Hosp Clin Pharm, Leuven, Belgium
[5] Katholieke Univ Leuven, Dept Imaging & Pathol, Leuven, Belgium
来源
关键词
lung transplantation; azithromycin; early lung allograft function; chronic lung allograft dysfunction; survival; BRONCHIOLITIS OBLITERANS SYNDROME; LONG-TERM AZITHROMYCIN; MAINTENANCE AZITHROMYCIN; AIRWAY INFLAMMATION; THERAPY; SURVIVAL;
D O I
10.1016/j.healun.2018.12.006
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Chronic lung allograft dysfunction (CLAD) is the single most important factor limiting long-term survival after lung transplantation (LTx). Azithromycin has been shown to improve CLAD-free and long-term survival, yet the possible impact on early lung allograft function is unclear. METHODS: A prospective, randomized, double-blind, placebo-controlled trial of pre-transplant and prompt post-transplant azithromycin treatment was performed at the University Hospitals Leuven. In each arm, 34 patients, transplanted between October 2013 and October 2015, were included for analysis. Study drug was added to standard of care and was administered once before LTx (1,000 mg of azithromycin or placebo) and every other day from Day 1 until Day 31 after LTx (250 mg of azithromycin or placebo). Primary outcome was an anticipated 15% improvement of forced expiratory volume in 1 second (FEV1, percent predicted) during the first 3 months post-LTx. Secondary end-points included length of intubation, days on ventilator, duration of intensive care unit and hospital stay, prevalence and severity of primary graft dysfunction, acute rejection, infection, and CLAD-free and overall survival. RESULTS: FEV1 was not significantly different between the 2 groups (p = 0.41). Patients treated with azithromycin demonstrated less airway inflammation, with lower bronchoalveolar lavage (BAL) neutrophilia and BAL interleukin-8 protein levels at Day 30 (p = 0.09 and p = 0.04, respectively) and Day 90 (p = 0.002 and p = 0.08, respectively) after LTx. Other secondary outcomes were not significantly different between placebo and azithromycin groups. CONCLUSIONS: Pre-transplant and prompt post-transplant azithromycin treatment was not able to improve early lung allograft function. However, the known anti-inflammatory properties of azithromycin were confirmed (NCT01915082). (C) 2018 International Society for Heart and Lung Transplantation. All rights reserved.
引用
收藏
页码:252 / 259
页数:8
相关论文
共 50 条
  • [1] Prophylactic Azithromycin Therapy After Lung Transplantation: Post hoc Analysis of a Randomized Controlled Trial
    Ruttens, D.
    Verleden, S. E.
    Vandermeulen, E.
    Bellon, H.
    Vanaudenaerde, B. M.
    Somers, J.
    Schoonis, A.
    Schaevers, V.
    Van Raemdonck, D. E.
    Neyrinck, A.
    Dupont, L. J.
    Yserbyt, J.
    Verleden, G. M.
    Vos, R.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2016, 16 (01) : 254 - 261
  • [2] A Prospective, Randomized, Placebo-controlled Trial of Pre-transplant and Prompt Post-transplant Treatment With Azithromycin to Improve Early Allograft Function and Outcome After Lung Transplantation (NCT01915082)
    Vos, R.
    Van Herck, A.
    Vanaudenaerde, B. M.
    Verleden, S. E.
    Van Raemdonck, D. E.
    Frick, A.
    Neyrinck, A. P.
    Verleden, G. M.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2018, 37 (04): : S88 - S88
  • [3] A randomised controlled trial of azithromycin to prevent chronic rejection after lung transplantation
    Vos, R.
    Vanaudenaerde, B. M.
    Verleden, S. E.
    De Vleeschauwer, S. I.
    Willems-Widyastuti, A.
    Van Raemdonck, D. E.
    Schoonis, A.
    Nawrot, T. S.
    Dupont, L. J.
    Verleden, G. M.
    EUROPEAN RESPIRATORY JOURNAL, 2011, 37 (01) : 164 - 172
  • [4] Post hoc analysis of a randomized trial of azithromycin in bronchiolitis obliterans syndrome after Lung transplantation (BOS); Lung function and survival
    Gan, Tji
    Ward, Chris
    Lordan, Jim
    Meachery, Gerry
    Fisher, Andy
    Corris, Paul
    EUROPEAN RESPIRATORY JOURNAL, 2017, 50
  • [5] A randomized controlled trial of tacrolimus versus cyclosporine after lung transplantation
    Hachem, Ramsey R.
    Yusen, Roger D.
    Chakinala, Murali M.
    Meyers, Bryan F.
    Lynch, John P.
    Aloush, Aviva A.
    Patterson, G. Alexander
    Trulock, Elbert P.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2007, 26 (10): : 1012 - 1018
  • [6] Long-Term Effects of Preemptive Azithromycin Therapy for CLAD After Lung Transplantation: Post Hoc Analysis of a Randomized Controlled Trial
    Ruttens, D.
    Verleden, S. E.
    Vandermeulen, E.
    Bellon, H.
    Van Raemdonck, D. E.
    Dupont, L.
    Vanaudenaerde, B. M.
    Verleden, G. M.
    Vos, R.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2015, 34 (04): : S45 - S45
  • [7] Felodipine and renal function in lung transplantation: A randomized placebo-controlled trial
    Hornum, Mads
    Iversen, Martin
    Oturai, Peter
    Andersen, Mads J.
    Zemtsovski, Mikhail
    Bredahl, Pia
    Bjarnason, Nina H.
    Christensen, Karl B.
    Carlsen, Jorn
    Moller, Christian H.
    Feldt-Rasmussen, Bo
    Perch, Michael
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2020, 39 (06): : 541 - 550
  • [8] Montelukast for Bronchiolitis Obliterans Syndrome After Lung Transplantation: A Randomized Controlled Trial
    Ruttens, D.
    Verleden, S.
    Vandermeulen, E.
    Bellon, H.
    Van Raemdonck, D.
    Yserbyt, J.
    Dupont, L.
    Vanaudenaerde, B.
    Vos, R.
    Verleden, G.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2016, 35 (04): : S43 - S44
  • [9] Montelukast for bronchiolitis obliterans syndrome after lung transplantation: A randomized controlled trial
    Ruttens, David
    Verleden, Stijn E.
    Demeyer, Heleen
    Van Raemdonck, Dirk E.
    Yserbyt, Jonas
    Dupont, Lieven J.
    Vanaudenaerde, Bail M.
    Vos, Robin
    Verleden, Geert M.
    PLOS ONE, 2018, 13 (04):
  • [10] High Doses of Vitamin D to Reduce Chronic Lung Allograft Dysfunction After Lung Transplantation: A Randomized Trial
    Vos, R.
    Ruttens, D.
    Vandermeulen, E.
    Bellon, H.
    Verleden, S. E.
    Van Raemdonck, D.
    Dupont, L.
    Yserbyt, J.
    Vanaudenaerde, B.
    Verleden, G.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2016, 35 (04): : S44 - S44